Loading...

Sunday, September 30, 2012

Inovio Pharmaceuticals, OncoSec Medical Bringing A Novel New Cancer-Fighting Technology To Market

Inovio Pharmaceuticals (INO) is another of quite a few developmental companies in the healthcare sector that has experienced a boost in both volume and price since the summer months and could be worth keeping an eye on as an advancing pipeline and a novel technology moves into the latter stages of Phase II development.  Inovio has pushed forward - through the development of its SynCon vaccine design process - a full pipeline of synthetic vaccines that are designed to universally treat multiple and emerging strains of a virus - instead of just focusing on treating a single strain, as is the standard of today's vaccine development. 
In addition to developing this technology to treat just various virus strains, however, Inovio has also applied the SynCon technology to treating multiple cancers, too. 

All in all, Inovio has nine programs in development with three of those in the Phase II stages.  Also noteworthy is that - according to documents contained on the Inovio website - six of those nine programs are funded by third parties, alleviating a portion of the monetary burdens of product development from Inovio, but also providing a sign of validation for the SynCon technology by those willing to fund its development.

With the three leading vaccine candidates moving into the latter stages of Phase II for the treatment of cervical dysplasia, leukemia and hepatitis C - and with the influenza and HIV pipeline moving through or having completed Phase I, investors have started to take notice of this company's potential to eventually jump head-first into the multi-billion dollar vaccine industry.  With SynCon's distinct advantage over current vaccines that treat just one virus strand, there's sound reason to believe that Inovio would be positioned to steal rapid market share, should any of its candidates advance to market.

Developing and selling flu vaccines is a huge business and companies developing such vaccines are always thrust to the speculative forefront when a rapidly-spreading virus strikes a large population.  Use the H1N1 'Swine Flu' scare of a few years ago as a prime example.  Evey company and its cousin that had its hand on vaccine-creating technology spiked in price in anticipation of possibly landing government funding for the endeavor of creating the 'cure'.  Cel-Sci Corp (CVM), for example, which is more widely known for its Phase III head and neck cancer vaccine, Multikine, spiked to as high as two bucks on the potential that it could transform its LEAPS technology into the H1N1 vaccine that the world was looking for at the time. 

In the case of Inovio, which also spiked to over two bucks at one point in 2009, the company has put its SynCon platform to use in a Phase I trial and - according to a press release issued earlier this month - interim analysis of the trial showed that its universal H1N1 influenza vaccine demonstrated proved effective against some of the most prevalent strains of H1N1 influenza from the past 100 years.  Inovio has also reported positive results in a similar H5N1 trial - among others - which offers multiple early validations of the technology in the clinical environment.  Although still early in development, a universal flu vaccine hits home to the average citizen - and investor - which could be a good reason why INO receives a nice price and volume spike anytime its universal flu vaccine reaches a definitive milestone.

Multiple trial catalysts are set to unfold over the next couple of quarters, namely interim analysis of ongoing trials, which - if positive - would provide investors another layer of validation and possibly provide enough spark to send shares back towards the dollar mark.

Another angle with which Inovio is attacking the vaccine market is the accuracy and effectiveness of its electroporation vaccine-delivery method.  Electroporation, as described on Inovio's websiteuses controlled, millisecond electrical pulses to create temporary pores in the cell membrane and allow dramatic cellular uptake of a synthetic DNA vaccine previously injected into muscle or skin.  This technology allows Inovio to more accurately and effectively direct its vaccine technology into the intended cells and has thus far in development "demonstrated best-in-class immune responses from DNA vaccines delivered using electroporation," also according to the above-linked website.

The combination of the SynCon pipline and the electroporation delivery technology could have the company positioned for success.  Investors should bear in mind, however, that the pipeline is still only in Phase II and the company will likely continue to need funding at points along the way, although management has stated in recent reports that there is enough cash on hand to last well into 2013.  Should any of this technology make it to market, however, the millions already pumped into development by all relevant parties could be quickly returned, given the sheer size of the vaccine market.

Electroporation may not be new to those who follow the more speculative side of the developmental healthcare sector.  OncoSec Medical Incorporated (ONCS) is another early-to-mid stage company demonstrating potential in the cancer treating sector after developing the OncoSec Medical System (OMS) based on electroporation technology licensed from Inovio.  Through OMS, OncoSec is more accurately and efficiently able to deliver therapeutic agents directly into cancerous cells without disturbing the surrounding tissue and has spawned two application paths for development from this technology - ImmunoPulse and NeoPulse.

ImmunoPulse, similar to the application used by Inovio, uses the electroporation process to spark a patient's immune system to target cancerous cells itself and, according to information published on the OncoSec website, "Initial evidence suggests that this gene therapy has the potential to not only treat cancer cells in the target area, but to also trigger immune responses affecting remote cancer cells outside the direct treatment area including distant lesions." NeoPulse, on the other hand, uses the OMS technology to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.

Both platforms have demonstrated early trial success, but results released earlier this year from a Phase III trial testing OMS in the treatment of head and neck cancer, however, demonstrated only equal efficacy with surgery - although quality-of-life for the patients was notably better when compared with patients receiving surgery. It's likely that many investors - who were looking for superior efficacy compared to surgery - were underwhelmed with those results and bailed out on their investment.  Before the results release, ONCS shares were trading for roughly triple the current prices and have only modestly recovered, thus far.

Looking to boost its proprietary technolgy, OncoSec announced that it had "secured an exclusive license for specific patented technology from the University of South Florida Research Foundation relating to the delivery of gene-based therapeutics via intratumoral and intramuscular electroporation." The patent, as described in the press release, relates to the ongoing ImmunoPulse Phase II trials for metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma and extends patent protection for the ImmunoPulse technology to the year 2024.

An additional clinical site for the ongoing MM trial was also announced this week.

With a highly speculative market cap of under twenty million, OncoSec - like Inovio - may offer investors a solid risk/reward play based on the potential of each company's respective applications of electroporation.  Each company has numerous opportunities to bring a product to market - as noted by the nine programs in development by INO and the six ongoing or planned clinical trials for OncoSec - and each is targeting very large markets, notably Inovio and the tens of billion dollar vaccine market.  Both are also trading notably off their respective 52-week highs, indicating that the right trial update news could spark another move higher, especially in the case of OncoSec where investors are looking for new enthusiasm following the early-2012 trial disappointment.

As always, each investor should conduct his or her own DD and devise entry and exit strategies accordingly while bearing in mind the inherent risky nature of the developmental healthcare sector.

Happy trading!!!

Disclosure: No positions.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published 26 September at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

Friday, September 28, 2012

AEterna In The Spotlight Following Bullish Analyst Coverage

Already a hot stock to watch based on an early-September move higher, AEterna Zentaris (AEZS) shares really caught fire late last week after Roth Capital Partners initiated coverage on the company with a rating of 'Buy' and a price target of $1.75, which values AEZS shares at more than double that of last Friday's close and more than triple the share price of just a few weeks ago.  As previously discussed, AEZS took a dive earlier this year after the high-profile failure of AEterna's Perifsone - then partnered with Keryx Biopharmaceuticals (KERX) - in a Phase III trials testing its effectiveness in fighting metastatic colorectal cancer made headlines. 

Although AEterna had numerous pipeline products still making their way through trials, including another Perfisone Phase III trial in multiple myeloma (MM), investors bailed en masse and shares hovered at fifty cents for the better part of the year.  A few weeks ago shares began to rebound again for essentially the same reasons as to why Roth Capital initiated bullish coverage of the company - the developing pipeline that is moving into the later stages of development.

In addition to the Phase III Perifisone, AEterna is also preparing to advance AEZS-130 to market.  AEZS-130 is a diagnostic test for Adult Growth Hormone Deficiency (AGHD), has already proven successful in Phase III trials and is slated for an NDA filing with the FDA in early 2013.  Should the product be approved, it would be the first orally-administered diagnostic test and has the potential to dominate the majority of its market, according to an Oppenheimer report this summer that tagged AEZS with a rating of 'perform.'  AEZS-130 has already received an Orphan Drug Designation in the United States and the company has also filed for a Fast Track Designation and rolling-NDA for the product.  Additionally, the company announced in August that the first patient had been treated in a Phase IIa trial for AEZS-130 in patients with cancer cachexia, adding potential beyond just the pending NDA.

Another late-stage pipeline product, AEZS-108, has already proven successful in multiple Phase II trials and is being prepared for a Phase III trial in the treatment of endometrial cancer.  Additional earlier-stage trials are also being planned for this product, providing the company with a fairly deep pipeline of potential which has attracted the attention of analysts, such as Roth Capital.

Volume was huge following the initiated coverage during this past Friday's trading session when shares pushed the one dollar mark, but tapered off at this week's open.  Shares were down by nearly eight percent on Monday, but such action is routine in this speculative sector as the day/swing/momentum traders often like to take quick profits during speculative price spikes in order to go looking for another fast mover.  While the average retail investor would also be wise to take some profit off the table when opportune price spikes allow one to do so, some may take the Roth Capital price target as a bullish enough sign to hang in there for the mid to long term as some of these near term catalysts play out.

What may benefit investors who took a stab at picking up half-dollar shares earlier this year after the Perifisone failure is that much of the market likely viewed AEZS as purely a Perifisone play, based on the fact that it was the most advanced pipeline product, had the moste immediate potential to rake in significant revenue and was the most high-profile product in the pipeline, in part due to the interest from Keryx shareholders, too.  When the colorectal trial failed, many ultimately discarded Perifisone as a failed product, but as the analysts have recently outlined, Perifisone is far from dead and the AEterna has a number of 'Plan Bs' in the works, too.

With a number of developments expected unfold under the next couple of quarters, including interim Perifisone MM results, launch of a Phase III AEZS-108 trial and the NDA for AEZS-130, there's reason to believe that AEZS could once again reclaim the dollar mark.  Based on the Roth Capital price target issued last week, the potential is also there for an even further rise.

Worth a look, although each investor should bear in mind the inherent risk of the sector and conduct his or her own DD.

Disclosure:  No position.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

icon

Cytosorbents: Building Blocks For The Future

Earlier this summer Cytosorbents Corp (CTSO) announced the official launch of CytoSorb in Europe.  CytoSorb had been approved last year in Europe for the treatment of conditions where high cytokines are present and the company has been taking a methodical and patient approach towards full commercialization in order to keep expenditures under control.  In conjunction with the launch, CytoSorb also appointed Dr. Christian Steiner, MD, to its European sales subsidiary as Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH.  The official launch was an highly-anticipated event by investors who believe that CytoSorb could become the new standard of care for severe sepsis and other indications of high ctyokines once momentum into the intensive care market builds.

Although additional trials will have to be conducted before an approval in the US is considered by the FDA, data from a European trial were convincing enough for the European medical regulators that CytoSorb was approved before the full trial was completed.  As a result CTSO shares tripled in price from the range of fifteen cents to nearly fifty.

Many are still unconvinced, however, with a US approval not in the immediate future.  These investors, in addition to many others, will be watching closely over the next few quarters to see if Cytosorbents can transform what could be considered a breakthrough device for the treatment of sepsis into a revenue-generating sales platform for the company.  According to the latest quarterly report filed by the company in August, the initial test phase of direct product sales to hospitals generated revenue of just under $50,000, but that was without an established sales force in place.  That's where Dr. Steiner and the European subsidiary come into effect - to build that force.

As the company grows its commercial success, its blood-purification technology has also received validation from various government agencies.  In August the company announced that it had been awarded nearly four millions dollars from the United States Defense Advanced Research Projects Agency (DARPA) Dialysis-Like Therapeutics (DLT) program to treat sepsis.  The award was pending satisfactory achievement of key milestones, according to information contained within the associated press release. 

Late last year Cytosorbents also received a Phase I SBIR (Small Business Innovation Research) grant by the US Army Medical Research and Materiel Command titled, "Investigation of CytoSorb Cytokine and Myoglobin Removal in the Treatment of Trauma."  The grant was worth $100,000, with an available option to bring in another $50,000. The awarding of this grant was noted as a prerequisite for the Phase II and III levels, which could bring the total numbers received by Cytosorbents to over a million dollars.

On Monday of this week it was noted that Cytosorbents was awarded the Phase II portion of this grant, which had been submitted for following the completion of the Phase I portion (the planning phase, according to Monday's press release).  The Phase II portion is worth up to a million dollars and will include animal studies, while Phase III - if also awarded - would include human studies.

If successful, the US Army grant and associated studies would provide the company with an "in" for further funding and sales.  The US Air Force has already expressed interest in the technology following the Army's lead - also according to Monday's release - and other services could follow suit.  Data from any associated studies would also be used to bolster the company's case in receiving additional approvals for its technology around the globe, including in the United States.

Cytosorbents shares were up by four percent on the news Monday, but the real short to mid term catalyst for the stock would be noticeably increasing sales numbers from the controlled roll-out in Europe.  The grants, awards and additional studies are providing the building blocks for a potentially robust future, but with a sales force now established in Europe, the primary focus of investors will be sales and revenue.  The more patient investor, however, will look at these other developments as another reason to accumulate for a potential mid to long term payoff.

Still a nice speculative story to watch, and one that has rewarded investors with at least triples in share price on numerous occasions before.

Disclosure:  Long CTSO.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

OptionsHouseoptionsXpress - Scary Charts

Wednesday, September 26, 2012

Weekly Stock Watch, Week of 24 September: AEZS, KERX, PPHM, AMRN, SGYP, IRWD, VGLD

At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well.

Although last week was one of sideways trading as the markets held their multi-year highs, this week and beyond could give investors some short term cause for concern.  The the third quarter earnings season is predicted to be soft and there are no real economic motivators expected to catalyst markets any higher than their current levels.  Stimulus talk and promises from the Fed in the US and from the European Central Bank across the pond fuelled much of the recent market run, but while stimulus is nice, the facts are that investors may key more on the sluggish economies as many believe - including this guy - that there is more potential for market downside than up.

Regardless, there's always going to be a few hot stocks and stories to watch.  Here's just a few of them...

Healthcare, Biotech, Pharmaceutical:

AEterna Zentaris (AEZS):  Shares of AEterna Zentaris have been on the move since the opening moments of September, but really caught fire late last week after Roth Capital initiated coverage on the company with a rating of 'Buy' and a price target of $1.75.  That target values AEZS shares at more than double that of last Friday's close and more than triple the share price of just a few weeks ago.  AEterna shares were cruising along earlier this year before the announced Phase III failure of Perifsone in metastatic colorectal cancer - which was partnered at the time with Keryx Biopharmaceuticals (KERX) - sent shares plunging.  Although Perifisone was - and still is - engaged in a Phase III trial for multiple myeloma (MM), investors used the colorectal failure as reason enough to lose confidence in the company and its stock.  As a result, shares remained trading for about half a buck since that time - until the rebound began a few weeks ago.

While Friday's monumental volume and notable share price rise did not continue into the new trading week this week - at least not at the onset - volume remained high as investors took note of the enthusiastic Roth price target.  Shares were down by nearly ten percent, however, as profit-takers likely booked some profits and moved on to the next quick mover.

As justification for the 'Buy' rating, Roth noted the company's advancing pipeline that consists of the aforementioned Perifisone, AEZS-130 - a diagnostic test for Adult Growth Hormone Deficiency (AGHD) which has already proven successful in Phase III trials - and AEZS-108, another anti-cancer agent that has already proven successful in multiple Phase II trials.  The company plans to file an NDA with the FDA early next year for AEZS-130 while AEZS-108 is being prepared for a near-term launch of a Phase III trial for endometrial cancer with other earlier-stage trials still planned.

As AEZS noted earlier in the year when the stock price collapsed from the two dollar level to fifty cents, investments in developmental companies are inherently risky so it's always a wise idea to bank profits into any speculative runs that may materialize before catalyst events unfold, but this is a story worth watching right now with the combination of price, volume and positive analyst coverage.

Peregrine Pharmaceuticals (PPHM):  The healthcare sector has the tendency to bring on a swift dose of reality quicker than most others, as evidenced by AEterna and Keryx earlier this year and again by Peregrine Pharmaceuticals on Monday morning.  Peregrine shares were trading for well over five bucks last week before crashing by over eighty percent at points on Monday when it was revealed that data from the latest bavituximab trial contained enough discrepancies to be considered unreliable.  Volume was through-the-roof, indicating a mass exodus of the stock by investors of all types and some also speculated that creditors will ask for their money back.  Aside from the already-distributed bad news, look for a slew of law firms to jump on the bandwagon looking to file class action suits on behalf of investors against the company - such action in the trend when events like faulty trials make news. 

While the trial disaster killed any investments made those who bought at the top, it's also important to emphasize the timing aspect of a speculative investment - PPHM was already a huge winner this year after moving from fifty cents to five bucks in quick time, but this week's reversal is a reminder that it's important to bank at least some profits when the opportune time arises.

It could be a while, in my opinion, before this one recovers.

Amarin Corporation (AMRN):  Shares of Amarin Corp opened the new trading week down by over six percent as investors still await news as to whether or not the FDA will ultimately grant a new chemical entity (NCE) designation for Vascepa, recently-approved for the treatment of very high triglycerides.  An NCE designation would provide the product more rock-solid protection from generic competition even as the company's patent portfolio surrounding the product grows.  A second delay in the NCE decision earlier this month sparked some high-profile debate as to whether or not the coveted designation would be granted, leading to the high volatility of AMRN trading and Monday's quick share price decline. 
.
Currently, however, AMRN may remind some of Human Genome Sciences before that company was bought out by GlaxoSmithKline (GSK) earlier this year.  Like Human Genome, Amarin has been long-speculated to eventually be bought out by a larger company.  Such speculation propelled shares to nearly twenty dollars once before but - also like Human Genome shortly before the buyout - have dropped significantly from previous highs as uncertainly keeps many investors on the sidelines.

Previous estimations valued an Amarin deal in the mid-twenties, but much of that depends on the outcome of the NCE status.  It's also worth noting that, NCE or not, AMRN shares may be slow to recover if the company indicates that neither a buyout nor a major partnership is in the works.  Given the potential of Vascepa over its lifespan, however, AMRN is still one to keep an eye on and could rebound significantly as commercialization picks up steam.

Synergy Pharmaceuticals (SGYP):  Synergy Pharmaceuticals has remained a hot company to watch leading into the fourth quarter of 2012 as a key trial catalyst could make or break the near to mid term future of this company and its share price.  As confirmed last month, Synergy's Phase IIb/III trial testing Plecanatide in the treatment of chronic idiopathic constipation (CIC) has completed enrollment and is on track for a December results release. Investor sentiment regarding this trial is positive, especially since Ironwood Pharmaceuticals' (IRWD) recently received an FDA approval for Linzess - a product previously known as Linaclotide which shares origins and a similar mechanism-of-action with Plecanatide. 

The Ironwood approval served as validation of the technology and proof positive that both companies recognize the close comparison was the entrance into a material definitive agreement by the two companies at the mid-September mark where it was agreed that Synergy would receive a license to Ironwood's method of use patents on plecanatide for the treatment of chronic constipation. The agreement further stated that Ironwood would receive "a low single digit royalty on net sales and both parties agreed not to challenge each other's patents covering certain GC-C agonists."

This licensing agreement helps to clear the path for Synergy to partner Plecanatide, which has demonstrated a superior side effect profile to Linzess in trials. During the Linzess trials, some patients experienced side effects that included severe cases of diarrhea that were extreme enough to force 6% of them to abandon the trial altogether. Thus far in developments for Plecanatide, no such side effects were noted, according to publicly-released information.

As Synergy undertakes numerous actions to position itself for late-year success, this will be a hot one to watch for the next few months.

Gold/Mining:

Valor Gold Corp (VGLD):  Shares of Valor Gold traded up by nearly ten percent at the week's open on more than double the average volume as the start-up exploration company advances plans to exploit Nevada's remaining gold deposits.  The company controls 8,000 acres of land in the prolific Battle Mountain-Eureka Gold Belt and along the Northern Nevada Rift and, according to a recent press release, has already discovered surface and shallow drilled gold on its Red Rock property.

Investors often find mining companies as a risky proposition as the future value of such companies is dependant on the intensity with which mining is conducted, a factor that cannot be gauged by following releases of public information.  Valor did, however, announce earlier this month a veteran presence on its 'Geological Advisory Board', demonstrating an early commitment to carrying out the business plan. 

Valor is an intriguing start-up to monitor as the company only went public months ago and has already stated that surface and shallow-drilled gold was found on its properties, which the company has also stated its intent to expand.  With gold - and companies successfully drilling for gold - a hot commodity over the past few years following the collapse of the global economy, it may be worth keeping a company or two in the sector on the watch list.

Roundup:  The 'Weekly Stock Watch' was a little late this week, but better late than never.  No ground-breaking economic news was released over the past week, nor is any expected to materialize over the coming week, but it'll be interested to see how the media plays the speculation surrounding the ability of the markets to hold these multi-year highs.  A push here or a shove there by those with influence could lead to a quick market decline, planned stimulus or not, while politicians from both sides of the isle are going to play the numbers to their favor.  Geopolitical factors overseas have drawn quite a bit of attention from the economy for the time being, but it's only a matter of time before that subject once again becomes center-stage for the presidential elections.  On a lighter note, Eli and G-Men soared over Calorina last Thursday night - looking like true Super Bow champs - and the Mets have actually put together a three game winning streak, for the guy that still cares. 

Looking towards next week, a predictably-dull earnings season will be upon us and the presidential debates will begin.

Sound exciting?  Probably not, but hey, that's why we have Goose and Football.

Happy Trading!!!

Disclosure:  Long SGYP, AMRN.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

icon

Saturday, September 22, 2012

Titan Pharmaceuticals: Back At A Buck

Shares of Titan Pharmaceuticals (TTNP) have traded in a relative range between sixty five and eighty cents since mid-April of this year, but a nice bump in volume over the past four trading sessions has once again helped the stock bash through the dollar barrier.  Investors who had been counting on the company landing a partner for Probuphine - a subcutaneous treatment for opioid addiction that utilizes Titan's proprietary ProNeura drug delivery system - were time and again disappointed by no news, leading to the share price slip to the sixties earlier this year.

Still no hope came in the company's latest quarterly report, filed last month.

Since Titan officials had previously indicated that the company would file for a Probuphine approval in 2012, it was quickly becoming crunch time to land a partner - and investors wondered once again if Titan could rise from the proverbial ashes, as it had just years before when the company was all but written off.

With the Probuphine filing still expected to take place, partner or not, within months, Titan shares were tipped during last week's stock watch for the potential to rebound on the news.  Titan trumped those expectations, however, and released news that the company had "entered into a Stock Purchase and Option Agreement with an affiliate of the potential licensee of the rights to commercialize Probuphine."

Additionally, last Friday's press release revealed that "Titan sold 3,400,000 shares of its common stock at $1.25 per share and agreed to an exclusive option period to execute the proposed licensing agreement (to October 31, 2012, which, if needed, can be extended to December 31, 2012) so that the potential partner can complete certain internal tasks."

The news was received of huge validation by investors that Titan would make good on its partnership promise and shares soared accordingly, hitting the dollar mark within days of the release on monumental volume, at least when compared to the stock's normal trading number.  Although a partnership deal is not yet finalized, the up-front stock and purchase agreement are indicative that both sides are intending to quickly seal the deal.  That said, given the timing of the news release and the stock purchase agreement, it's safe to assume that the two sides are close.

As mentioned above, it is still expected that in October the company will file with the FDA for the approval of Probuphine and it now looks like the company could have some high-profile backing in doing so.  Probuphine , which is also being investigated for its potential in treating chronic pain, would be the first product brought to market by the company, although Titan had a royalty agreement with Vanda Pharmaceuticals' (VNDA) for the schizophrenia drug Fanapt.

With the partnership deal all but finalized, Titan has regained some lost credibility with shareholders and is again a relevant player as a potential growth and rebound story - if not a buyout candidate, too.  The ProNeura drug delivery technology alone could be worth a bundle to a larger pharmaceutical company, given the trend towards controlled-release delivery platforms due to the swift crackdown on abuse and misuse of prescription drugs.

Now back in the ball game, developments could come quick.  The Probuphine filing should now be considered imminent as is the expectations of a finalization of partnership talks.  The volume that has been moving the stock is for real, as was the move back to a dollar so it may again be time to entertain the thoughts that this stock could return to its 52-week highs, if not surpass them.

Should investors expect the monumental gains realized when shares ran from a penny to two bucks a few years ago?  Probably not, but if Probuphine makes it past the FDA and if the partnership deal does in fact play out, then it's likely that another upside move could take shape.

As Yogi Berra said, "It ain't over 'til it's over," so nothing is a done deal until it's a done deal, so it's still worth entertaining the risk - but it looks like Titan is back on track, and those that took advantage of the dip into the sixties are already sitting pretty.

Stay tuned.

Disclosure:  Long TTNP.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



Thursday, September 20, 2012

AEterna Zentaris: A Potential Rebound And Growth Play Based On Pipeline Progress And Pending Catalysts

AEterna Zentaris (AEZS) was cruising along earlier this year with a share price four times the current levels, a pipeline full of potential and results from a Phase III trial testing the company's lead product candidate, Perifisone, in the treatment of metastatic colorectal cancer soon to be released. Investor confidence was also building as shares of both AEterna and partner Keryx Biopharmaceuticals (KERX) were quickly heading higher leading into the trial catalyst. All that changed overnight, however, when it was announced that Perifisone failed the Phase III trial. AEterna shares plunged, as did those of Keryx, and neither company has yet to return to the pre-results highs. AEterna, actually, remained stagnant over the course of the summer, trading at well below the dollar mark as investors demonstrated a loss of confidence in Perifisone, which was (and still is) being investigated in a Phase III trial for multiple myeloma (MM).

In general, the short term minded investors reacted to the immediate news, bailed out and went looking for quicker gains elsewhere. While that strategy is typical in today's environment of seeking quick gains, others may have seen some benefit is slow accumulation of AEZS shares with a more patient eye towards the development of the rest of the pipeline - which still includes Perifisone, too. Those investors may start to see quick returns of their own as volume has been rolling into AEZS trading over the past couple of weeks, and the share price has also followed higher.

At the open of September the stock was trading at fifty cents and below, but a swift influx of trading volume last week boosted shares to nearly seventy cents before the profit-takers jumped ship and sent shares back to the low sixties. Such a quick barrage of price and volume, however, has brought additional eyes to the AEterna story and many may like what they see.

One outcome of the failed Perifisone trial earlier this year was that all North American rights to the drug were returned to AEterna from then-partner Keryx, leaving AEterna to most benefit from any future successes. The MM trial, as mentioned, is still trucking along in Phase III and interim results from the trial are expected to be released in the first quarter of next year, according to a current company presentation available on the company website.

Investors may not give due notice to the advancement of Perifisone after its noted failure in the colorectal indication, but there are numerous instances, as outlined in a report earlier this year, of cancer-fighting product candidates failing in the treatment of one indication, only to prove successful in treating others.

Perifisone still remains the company's flagship product candidate and successful interim results early next year could reinvigorate investor interest in the product.

Beyond Perifisone, however, the company boasts a deep pipeline of potential and offers the company multiple paths for success. Such a pipeline is always a positive for a developmental stage company, as it provides the company with room for error (although it should also be noted that multiple pipeline products also means more money needed for development). For instance, Perifisone failed one trial, but another was already under way; and for investors who discount the potential of Perifisone altogether because of the trial failure, there is a lot more in the pipeline to take a look at, both clinical and pre-clinical.

The most advanced of 'the rest of the story' is AEZS-130, a diagnostic test for Adult Growth Hormone Deficiency (AGHD) which has already proven successful in Phase III trials and for which the company plans to file an NDA with the FDA early next year. Should the product be approved, it would be the first orally-administered diagnostic test and has the potential to dominate the majority of its market, according to an Oppenheimer report this summer that tagged AEZS with a rating of 'perform.' AEZS-130 has already received an Orphan Drug Designation in the United States and the company has also filed for a Fast Track Designation and rolling-NDA for the product. Additionally, the company announced in August that the first patient had been treated in a Phase IIa trial for AEZS-130 in patients with cancer cachexia.

Between Perifisone and AEZS-130, investors have ample catalyst and milestone events to monitor with regards to this company.

A little earlier along in development is AEZS-108, another anti-cancer agent that has already proven successful in multiple Phase II trials and is being prepared for a near-term launch of a Phase III trial for endometrial cancer. Additional Phase I and II trials are also planned, positioning AEZS-108 as the AEterna product with potentially the most robust market potential.

According to the latest quarterly report, AEterna had nearly $40 million in the bank as of the end of June, 2012, with a monthly burn rate of just over $2 million. That cash cushion reduces investor risk of immediate massive dilution, but investors may also keep in mind that additional funds may be required at some point during development.

In the meantime, the price and volume action over the past couple of weeks could be an indication that investors may have gotten over the early-year Perifisone failure and are ready to again entertain the potential of the remaining pipeline candidates. While a move back towards the early-year highs is unlikely at this time, there is reason to believe that the stock could again push the dollar mark over the near to mid term, based on the advancement into late-stage trials of AEZS-108, the advancement to FDA approval of AEZS-130 and the pending interim look at the Perifisone MM trial. The potential for other sporadic interim and actual Phase II trial news could also hit the wires at any given time.
Lost and forgotten for the better part of 2012, AEZS may be in the midst of a fine period of recovery, and it looks like the pipeline potential is again grabbing attention.

Disclosure: No position.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213



iconOptionsHouse

Wednesday, September 19, 2012

Advanced Medical Isotope Corporation: Making A Move In Nuclear Medicine

Through molecular imaging, therapy, and nuclear medicine, medical isotopes - a form of chemical element with the same atomic number as another element but with a different atomic mass (for the chemistry buffs out there) - are used to diagnose, manage and treat a wide variety of diseases, most notably of which may be cancer.  While the precise definition of the science behind a technology is noteworthy, the average investor ideally needs to know what a technology does and how much potential it could have on the market at certain points in the future.  It also helps to know the demand for a particular product or technology. 

In this case, as mentioned above, medical isotopes are used in the identification and treatment of various diseases - including cancer and heart disease - and their use is already a part of a proven multi-billion dollar market, and demand may be growing due to the evolution of science and other geo-political factors.  The medical profession is currently looking to use low-enriched uranium (as opposed to highly-enriched) to create these isotopes due to regulations imposed by global nuclear treaties and concerns that supporting the production of such products in foreign countries could be an incentive to increase their respective supplies of bomb-grade uranium.

Advanced Medical Isotope Corporation (ADMD), a company whose stock has recently set a new 52-week high after tripling in price on the prospectes of recently-realized and some still-developing catalysts, may have positioned itself - through its key partnerships and growing distribution channels - as a leader in the US to meet the growing demand for medical isotopes.  Additionally, the recent acquisition of a key license to an exclusive technology may have also positioned the company to usher in the next generation of such technology.

As described by Dr. Alan Walter, Chair of the Scientific Committee, in a presentation published on the company's home page, Advanced Medical is deveoping its proprietary technology to create what he terms as "smart bullets" - meaning isotopes that target only cancerous cells, while leaving healthy cells unharmed.  This technology is a step beyond and preferable to the currently-standing chemotherapy and radiation treatments that help to target cancerous cells, but also damage the healthy tissue.

An April acquisition demonstrates AMIC's progress along these lines as the company, at that time, acquired a license and eight patents relating to an injectible radiogel technology that can deliver Yttrium-90 "microspheres" directly into cancerous tissue.  Yttrium-90 is an already-established medical isotope with numerous applications in cancer treatment, but its application in the radiogel holds significant advantages over current treatments, especially because the radiogel allows only a minimal amount of radiation to escape, thereby causing little - if any - damage to healthy tissue.  In essence, this is the comparison to the "smart bullet" described by Dr. Walter.  That noted benefit could quickly enable the product to steal market share from the current standar, should it gain acceptance into the community.

The ADMD share price started move after the announcement of this deal, most likely because the company now had another angle at which to attack a lucrative market already loaded with potential.  Shares have settled in a tight range since, however, and are trading at a very attractive market cap, considering the potential of the technology on hand.  Also adding to the drop from the highs could have been a mid-August 8k filing announcing the granting of three million shares that became fully-vested at the time of issuance.

That said, with a solid management and scienctific team at the helm and numerous technologies and business growth strategies with which to attack the market, ADMD could have the makings of a nice, speculative growth story for investors willing to take the small-cap risk that always accompanies the small-cap reward potential.

The foundations for success are well in place, the portfolio is stocked with currently-distributed products, and emergine technologies could take AMIC to the next level.

There are no sure things in this business, but this is a story that could be worth watching.

Disclosure:  No position.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

icon

Tuesday, September 18, 2012

OncoSec Medical: One To Keep An Eye On, Given Recent Developments And Pipeline Potential

OncoSec Medical (ONCS) - with a market cap of right around twenty million and a share price of just over twenty cents - is still chugging along as a potentially attractive risk/reward play for investors looking to take a chance on a new method of cancer treatment based on a novel technology.  OncoSec, as previously noted, has developed the proprietary OncoSec Medical System (OMS), which uses a process known as electroporation to more accurately and efficiently deliver therapeutic agents directly into cancerous cells without disturbing the surrounding tissue.  Such a technology, should it prove successful through development, could help ease the cost burdens associated with cancer treatment today as existing treatments could become more effective and side effects could be minimized.

From the OMS, OncoSec has spawned two application paths for which the company has concentrated development -  ImmunoPulse and NeoPulse.  ImmunoPulse uses the electroporation process to spark a patient's immune system to target cancerous cells itself and, according to information published on the OncoSec website, "Initial evidence suggests that this gene therapy has the potential to not only treat cancer cells in the target area, but to also trigger immune responses affecting remote cancer cells outside the direct treatment area including distant lesions."  NeoPulse, on the other hand, uses the OMS technology to destroy cancer cells using less harmful doses of bleomycin, a highly effective but also highly toxic anti-cancer drug.

Both platforms have demonstrated early trial success, but results released earlier this year from a Phase III trial testing OMS in the treatment of head and neck cancer, however, demonstrated only equal efficacy with surgery - although quality-of-life for the patients was notably better when compared with patients receiving surgery.  It's likely that many investors - who were looking for superior efficacy compared to surgery - were underwhelmed with those results and bailed out on their investment.  Before the results release, ONCS shares were trading for roughly triple the current prices.

Even though the share price has not recovered from the March drop, however, there is evidence that many eyeballs are still watching this stock. 

Early last week the company announced that it had "secured an exclusive license for specific patented technology from the University of South Florida Research Foundation relating to the delivery of gene-based therapeutics via intratumoral and intramuscular electroporation."  The patent, as described in the press release, relates to the ongoing ImmunoPulse Phase II trials for metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma and extends patent protection for the ImmunoPulse technology to the year 2024.

While the extended exclusivity of the exclusive license adds inherent value to the company and its pipeline technology, the volume spike that associated the announcement could have been evidence that investors are watching - and waiting to pounce when the right news hits.  When investors take a 'wait and see' approach to a speculative stock such as ONCS, spontaneous reactions to any news release - such as that seen last week - could be an indication that the stock is being heavily watched.  In such cases, stocks can move quick as investors move in when the news they are looking for hits - such as positive interim or actual trial results.

On the other hand, the volume boost could also have been related to a company presentation at a high-profile investor conference last week, in which case the boost could be a validation of investor interest in the company.  Either way, overall volume has been up this month and the share price has also inched modestly higher. 

With numerous trials underway testing a novel technology and with a company market cap of right around twenty million, ONCS is just the type of speculative play worth keeping an eye on.  At this point investor sentiment remains skeptical following the mentioned Phase III results from earlier this year, but a turnaround could come quick at any hint that the technology is proving more effective in the still-ongoing trials.  It's also worth noting that although the efficacy in the head and neck cancer trial may have only been equal to that of surgery, there is something to be said for equal efficacy, but improved quality-of-life and lower associated costs.  Less-intrusive and less-costly is the name of today's healthcare game, and OMS plays right into that trend.

Is that alone enough to draw in new investors?  Maybe not, but the ONCS 52-week highs that were just about five times the current price are a sign that investors who once again become enthusiastic about this company's technology could move the share price quickly.

A story still developing and worth keeping an eye on.

Disclosure:  No position.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
iconOptionsHouse

Weekly Stock Watch, Week of 17 September: AMRN, SGYP, IRWD, FRX, SSH, NBS, ACTC, AEZS, KERX, TTNP

At the conclusion of each week, VFC's Stock House examines some news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well.

The markets flew last Thursday afternoon and Friday morning after much-anticipated comments from the US Federal Reserve indicated that stimulus for the ailing economy would continue to be forthcoming until the economy picks up steam on its own.  Investors liked the news and sparked the run that built on momentum created the previous week when the European Central Bank (ECB) issued similar comments of its own. 

Encouraging as the stimulus and the new multi-year market highs may seem, however, investors will ask this week whether the current state of the global economy justifies such enthusiastic market returns, or whether September's run is just a head fake, with a move to the downside all but inevitable.  Judging by some weekend headlines and uncertainties in geopolitical flash-points this week, it's safe to assume that much of the economic media coverage is ready to head south - and maybe justifiably so.

Comments from both the Fed in the US and from officials of the ECB in Europe were encouraging for investors over the past couple of weeks, but by no means were those comments unexpected or a surprise.  Additionally, none of those comments can mask the realities of citizens in most major economies leaving their respective work forces as global growth continues to slow - all while the US and European economies continues to roll sluggishly along.

The coming earnings season has yet to be labeled a pending disaster, but there have been signs by some big players that the season will most likely disappoint.  Few are likely to be caught by surprise from these potential developments, but with market sentiment already having been so high for so long, it's arguable that the potential for downside outweighs the potential for upside right now - especially with presidential elections right around the corner and growing global unrest again dominating the news headlines.

Up market or down, it's likely another exciting week ahead of us.  As always, there are sure to be plenty of stocks and stories to keep an eye on. Here's just a few of them...

Healthcare, Biotech, Pharmaceutical:

Amarin Corporation (AMRN):  As exciting and much-watched as Amarin Corporation is these days, it's tough to keep this one off the watch list.  Last week another wrench was thrown into the storyline when an 8k filed by the company indicated that the FDA had again delayed issuing a final decision on whether or not to grant a new chemical entity (NCE) designation for Vascepa.  Vascepa was approved back in July for the treatment of very high triglycerides and an NCE designation would provide the product years of protection from generic competition.  Many investors and potential buyers of the company view NCE as much more rock-solid protection than patents, being that patents can be challenged in court and a company can easily burn through tens of millions of dollars - at least - defending those patents. 

Amarin, however, has been building a solid portfolio of patent protection and it could be argued by the other side that such patent protection will also provide the near air-tight protection that investors and potential buyers (or partners) look for in an investment.

The delay last week sparked a slew of new articles from various media publications - some quite negative - that led to a week of wild volatility that saw AMRN shares dip to below the thirteen dollar mark for a time on Wednesday before recovering to back over fourteen by the end of the week.

Another event may have led to the late-week share price rebound. 

It has been long-speculated that Amarin would eventually be bought out by a larger company and such speculation propelled shares to a price of nearly twenty dollars early last year.  Some may believe that talks along those lines may be materializing into a reality since the company pulled itself from a major investor presentation this week.  While one could only speculate as to why the company pulled out, advanced buyout or partnership talks are valid reasons why a company would take such action.  Based on the potential valuation of Vascepa over its lifespan, it's also a valid reason why the AMRN share price quickly recovered following the mid-week drop.

Synergy Pharmaceuticals (SGYP):  Synergy Pharmaceuticals is another company that should be considered a potential buyout play based on the development of Plecanatide chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.  As described in previous weeks, Plecanatide shares origins and the same mechanism of action with Ironwood Pharmaceuticals' (IRWD) recently-approved Linzess, previously known as Linaclotide.  Plecanatide may turn out to be the superior product, however, since Linzess - already partnered with Forest Laboratories (FRX) - was noted to cause severe bouts of diarrhea in patients during trials while Plecanatide's side effect profile thus far in development has been stellar.  Those early results will be in the spotlight this December as key Plecanatide Phase IIb/III trial results are slated for release.  Results from this trial will not only potentially confirm earlier results, but it also provides investors with a relatively near-term catalyst that could spark a move as quickly as the one that materialized earlier this year that ran shares to seven dollars.

Synergy shares also received a modest boost to above the five dollar mark following the approval Linzess a couple of weeks ago.  That spike quickly subsided, but the full potential of the company and its chief developmental product may not yet be realized by investors, especially in comparison to IRWD's market cap.  Some analysts have been noted to agree, as demonstrated by near-to-mid term SGYP price targets of at least double that of the current share price.

As the Plecanatide story plays out, Synergy made another move last week to boost its value in the eyes of investors and potential buyers of the company.  On Wednesday it was announced that the company would expand its gastrointestinal (GI) pipeline by filing an Investigational New Drug (IND) application for SP-333 in the treatment of inflammatory bowel disease.  While still very early in development, the IND broadens the company's GI platform and could potentially position Synergy to become a quick leader in the field of GI treatment, given the other indications the company intends to treat with Plecanatide.  The initiation of trials is planned for later this year, offering investors and potential buyers of Synergy a second pending catalyst for late-2012.

Shares spiked by over five percent on Friday as investors absorbed the prospects of this company building a second pipeline product, but the real short term interest revolves around Plecanatide success.

Given Friday's rise, however, SGYP will be one to watch this week.

Sunshine Heart (SSH):  Last week a volatile and high-volumed week for Sunshine Heart after investors reacted to some bullish analyst coverage the previous week that slapped a price target on SSH of nearly double where shares were trading at the time.  The price pop sent shares to well over the nine dollar mark from under seven before closing Friday at $8.74, still on increased volume.  Canaccord Genuity initiated coverage of the company with a 'buy' rating and a price target of eleven dollars. In justifying the new rating, Canaccord cited the encouraging results of the North American feasibility trial for the C-Pulse Heart Assist system, a device that has thus far proven to not only halt the progression of heart failure in patients with Class III and ambulatory Class IV heart failure, but potentially reverse it as well.

As noted in previous weeks, C-Pulse also received an approval in Europe this summer, making it a likely scenario that the company could register its first commercial sales in conjunction with the launch of a US trial that is planned to begin within months and will be designed with an eventual FDA approval in mind.

With the initiation of analyst coverage, all the pieces may be falling in place for Sunshine.  The company's cash position is solid thanks to a stock offering conducted months ago, which - according to an amended S1 - included the backing of a major "strategic partner" who also sent a member to the Sunshine board as an observer.  The offering money gives Sunshine enough cash to last through the mid-way point of the upcoming US trial, a key milestone event that could then spark the yet-to-be-named "strategic investor" to take additional action.

Last week's volatile week for Sunshine should put some new eyeballs on the stock this week.

Neostem, Inc. (NBS):  In just the past four weeks, Neostem has made some significant strides in its share price and an influx of trading volume also supported the run.  NBS began climbing a few months ago on positive pipeline progress and then received a further boost as the company decided to divest its majority stake in a subsidiary, Erye, in order the strengthen its balance sheet. Then, recently, the company also reported that it had received approval from a data monitoring committee to continue moving forward with its Phase II PreSERVE trial, designed to measure the effectiveness of AMR-001 in preventing or treating major cardiac events following heart attacks.  Such approvals are positive in the sense that they provide a firm validation of trial progress, which is especially noteworthy in the sector of regenerative medicine where the technology is still relatively unproven. The intended market for AMR-001 - especially considering its potential use in also treating congestive heart failure - stands in the billions.

Regenerative medicine has been identified by many as being the next significant medical breakthrough and the early results by companies such as Advanced Cell Technology (ACTC) and Neostem are consistently providing investors with solid validation of the technology as a new hope for the future of medicine and as a target for investing dollars.  Such validation could be a key reason why NBS continues to attract investor interest, which consequently leads to a higher share price.

Last week Neostem announced key news in regards to protecting its technology as subsidiary Amorcyte, LLC announced "a significant expansion in its claims granted to protect the use of CD34+ cells, acquired from blood or bone marrow, to impart a therapeutic benefit to tissue sustaining an ischemic injury."  The company received notice of additional patent protections from both the US and Japanese patent offices, reinforcing the company's potential to bring AMR-001 to market on a broad and international scale.

One major benefit to an investment in NBS as a 'stem cell choice' is the fact that the company already has a growing revenue base.  In early 2011, NeoStem completed the acquisition of Progenitor Cell Therapy a large-scale contract manufacturing facility that has the potential to bring in additional revenue to fund its clinical-stage pipeline candidates. Revenue generated by this division has already led to a growth rate of 95% during the past two reporting quarters, according to numbers presented the latest quarterly report.

By no means should investors believe that Progenitor revenue will alleviate any additional need for financing, Neostem has positioned itself for success with this deal.

Last week's price and volume spike should have this one back on the radar.

AEterna Zentaris (AEZS): Not much has been heard from AEterna Zentaris since April when the company's Phase III Perifisone - partnered at the time with Keryx Biopharmaceuticals (KERX) - failed Phase III trials and company shares plunged.  During this past trading week, however, AEterna shares received a swift spike in share price while trading volume also picked up pretty heftily.  In fact, on Friday alone volume was up by nearly five times the daily average.  No news accompanied the rebound in share price, but the company has or is slated to present at a few high-profile investor conferences and investors may be paying the stock some attention again, noting the pipeline potential beyond just the failed Perifisone indication.

Perifisone still remains the company's most advanced product candidate and another Phase III trial testing the treatment against multiple myeloma is ongoing.  Investors may pay little mind to the continuation of its development following the noted failure, but there have been instances in the past of other drugs failing in one tumor type, but succeeding in others, as noted by a report earlier this year.  Additionally, AEZS has multiple product candidates in Phase II trials and yet others in pre-clinical development.  With that being the case, there could be some merit to an argument that says AEterna shares have been oversold since the severe drop-off this April and could still provide investors with a nice risk/reward story while shares remain suppressed.

Given the ferocity behind last week's price and volume spike, however, this stock's time of vacationing on the beaches of Spain for the summer could be numbered as investors jump in again.  At the close of August the company announced that the first patient had been treated in a Phase IIa trial for AEZS-130 in patients with cancer cachexia.  For a small company looking to recover from a failed late-stage trial, the positive progression of other pipeline candidates proves crucial for a rebound.

With company in the spotlight again via investor conferences and volume surges such as that seen last week - especially on Friday - this could be a hot one to keep an eye on.

Titan Pharmaceuticals (TTNP):  Titan shares were tipped during last week's stock watch for having some possible catalysts pending, but TTNP made even more noise last week and quickly flew to the dollar mark on monumental volume - in relation to daily averages - as the company announced that it had "entered into a Stock Purchase and Option Agreement with an affiliate of the potential licensee of the rights to commercialize Probuphine."

According to Friday's release, "Titan sold 3,400,000 shares of its common stock at $1.25 per share and agreed to an exclusive option period to execute the proposed licensing agreement (to October 31, 2012, which, if needed, can be extended to December 31, 2012) so that the potential partner can complete certain internal tasks."

This news is huge for Titan shareholders as it is finally a firm validation that the company is, in fact, in talks to partner Probuphine.  Quarter after quarter company officials noted that talks were underway, but this is the first definitive proof that they are.  While the final terms of any potential deal are still unknown, the up-front stock and purchase agreement are indicative that both sides are intending to quickly seal a licensing deal.

It's expected that in October the company will file with the FDA for the approval of Probuphine in the treatment of opioid addiction.  Probuphine is also being developed for the treatment of chronic pain and utilizes the subcutaneous ProNeura drug delivery system, which comes with inherent value of its own given the abuse and overuse of common prescription drugs today.

With a new deal looking to be in the works and a nice boost in share price, it's time to keep an eye on Titan again.

Roundup:  With the latest quarter coming to a close, speculation will start trending towards quarterly results that will again start in earnest within weeks.  Many predict a disappointing season, although since that is already largely assumed, the numbers alone may not influence market trends unless we see a lot of "worse than expected" results.  On the other hand, general sentiment could head south quickly, given that most analysts and pundits believe that the market has more downside potential than upside right now.  That means we may be heading to the valley side of the "peaks and valleys" stock market game.  There will always be success stories, though, whether the market goes up or down and that is where an investor's solid due diligence can pay off heftily.

This week was a somewhat abbreviated Weekly Stock Watch, but hey - Eli Manning had 500 passing yards. 

Score.

Disclosure:  Long TTNP, AMRN, SGYP.

Contact VFC's Stock House: vfc@vfcsstockhouse.com

Originally published at: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

iconOptionsHouse




Follow by Email